DNLI
Denali Therapeutics Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 25 ▲ Denali Therapeutics announced FDA accelerated approval of AVLAYAH™ (…
- May 21 ▼ Denali Therapeutics and Biogen announced that the Phase 2b LUMA stud…
- May 21 FDA: Biogen and Denali Therapeutics Provide Update on Phase 2b…
- Jun 18 ▲ Denali Therapeutics (DNLI) announced the sale of its Rare Pediatric…
- Jun 18 ▲ Denali Therapeutics announced the sale of its Rare Pediatric Disease…
- Jun 18 Contract: Denali Therapeutics Enters Agreement to Sell Rare Pediatri…
- Aug 6 Denali Therapeutics reported Q2 2026 results with AVLAYAH generating…
- Aug 11 ▼ 1 insider sell $71.6K at $25.07
- Sep 1 to Sep 4 ▼ 3 days of insider sells: $363.7K by 3 insiders, avg $22.93
- Oct 30 FDA: Denali Therapeutics Receives 2026 Prix Galien USA Award fo…
- Nov 3 ▲ Denali reported Q3 2026 AVLAYAH net product revenue of $17.8M, accel…
- Nov 13 Wells Fargo initiates
Signal stack
Where each data set points today.
- InsidersBEARISH
3 insiders sold $435.3K.
- InstitutionsMIXED
Q3 2026: 25 added (0 new), 17 trimmed or exited.
- AnalystsBULLISH
24 of 26 rate it Buy or better. Every target is above the price.
- EstimatesFLAT
Current-quarter EPS estimate −$0.626 → −$0.618 over 90 days. 5 up, 1 down in 30 days.
- Short sellersSTEADY
Short interest −5.0% to 14.69M shares. 9.9 days to cover, ≈9.2% of shares.
- TrendRANGE
8% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| Pictet Asset Management Holding SA | TRIM | $33.0M |
| MORGAN STANLEY | ADD | $28.3M |
| Nuveen, LLC | ADD | $17.7M |
| MARSHALL WACE, LLP | ADD | $16.6M |
| AMERICAN CENTURY COMPANIES INC | TRIM | $9.5M |
| CITIGROUP INC | TRIM | $6.9M |
| Hudson Bay Capital Management LP | DOUBLED | $5.4M |
| ALPS ADVISORS INC | ADD | $4.4M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
26 analystsPrice is below the lowest target. Median implies +94%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 13, 2026 | Morgan Stanley MAINTAIN | Overweight |
| Nov 13, 2026 | Wells Fargo INITIATE | Overweight |
| Nov 4, 2026 | Morgan Stanley MAINTAIN | Overweight |
| Nov 4, 2026 | Wedbush MAINTAIN | Outperform |
| Nov 4, 2026 | BTIG REITERATE | Buy |
| Aug 25, 2026 | B. Riley Securities MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Chin Peter Scott Chief Medical Officer Sep 4, 2026 | SELL | $36.9K |
Thornberry Nancy Director Sep 2, 2026 | SELL | $14.6K |
Thornberry Nancy Director Sep 2, 2026 | SELL | $247.3K |
Schuth Alexander O. COFO and Secretary Sep 1, 2026 | SELL | $64.9K |
Watts Ryan J. President and CEO Aug 12, 2026 | GIFT | 32,220 sh |
Schuth Alexander O. COFO and Secretary Aug 11, 2026 | SELL | $71.6K |
BAKER BROS. ADVISORS LP Director Jun 3, 2026 | AWARD | 19,226 sh |
BAKER BROS. ADVISORS LP Director Jun 3, 2026 | AWARD | 6,408 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.62 | -$0.69–-$0.50 | +0.6% | $32.6M |
| Next Q | -$0.64 | -$0.69–-$0.58 | +7.6% | $39.7M |
| Current FY | -$2.00 | -$2.70–-$1.50 | +10.0% | $53.9M |
| Next FY | -$2.26 | -$2.66–-$1.50 | +6.7% | $164.3M |
Washington
Short side
FINRA· Oct 30, 2026SecBot reports
12 filings · 5 press releases · 3 bullish · 0 bearish · 2 mixed · 7 neutral- NEUTRAL SC 13G/ANov 16, 2026
T. Rowe Price Investment Management filed an amended Schedule 13G disclosing a 12.3% passive stake in Denali Therapeutics as of September 30, 2026, representing 19,634,011 shares. The filing is a routine passive update with no change in investment intent, and the stake size is consistent with a…
🔒 Fresh report (last 24h), subscribers only
- BULLISH 8-KNov 3, 2026
Denali reported Q3 2026 AVLAYAH net product revenue of $17.8M, accelerating from $3.6M in Q2, and…
The rapid AVLAYAH revenue ramp and strong Q4 guidance validate commercial execution and support the platform thesis. Watch for Q4 actuals and the zafinofusp alfa BLA submission in 2027, which would…
- NEUTRAL PRESS-RELEASENov 3, 2026
Denali Therapeutics reported Q3 2026 AVLAYAH net product revenue of $17.8M, its second full…
Monitor Q4 2026 AVLAYAH revenue against the $30.0M-$32.0M guidance to gauge commercial trajectory. Key pipeline catalysts in 2027 include zafinofusp alfa BLA submission, DNL593 Phase 1/2 data, and…
- NEUTRAL PRESS RELEASEOct 30, 2026
Denali Therapeutics announced that its FDA-approved drug AVLAYAH (tividenofusp alfa-eknm) received…
The award is a reputational boost but does not change the fundamental outlook. Monitor confirmatory study results for AVLAYAH's full approval and pipeline progress for DNL628 and DNL921 in…
All DNLI filing & press-release reports (17)
- SC 13G/A reportNov 16, 2026
- 8-K reportNov 3, 2026
- PRESS-RELEASE reportNov 3, 2026
- PRESS-RELEASE reportOct 30, 2026
- PRESS-RELEASE reportOct 22, 2026
- CLUSTER reportSep 9, 2026
- CLUSTER reportSep 4, 2026
- 8-K reportAug 6, 2026
- PRESS-RELEASE reportJul 27, 2026
- 8-K reportJun 18, 2026
- PRESS-RELEASE reportJun 18, 2026
- INST-CLUSTER reportJun 11, 2026
- PRESS-RELEASE reportMay 21, 2026
- PRESS-RELEASE reportMay 7, 2026
- 8-K reportApr 3, 2026
- PRESS-RELEASE reportApr 3, 2026
- PRESS-RELEASE reportMar 25, 2026